CSL sees highest filings and grants during August in Q3 2023
CSL has been focused on protecting inventions in South Korea(KR) with 13 publications in Q3 2023
The South Korea(KR) Patent Office dominates the patent filings and grants with nearly 23% filings and 5% grants. The South Korea(KR), Israel(IL), United States(US), and Australia(AU) patent Office are among the top ten patent offices where CSL is filings its patents. Among the top granted patent authorities, CSL has 23% of its grants in United States(US), 14% in European Patent Office(EPO), and 5% in South Korea(KR).
Amgen could be the strongest competitor for CSL
Amgen and Johnson & Johnson secured the top positions according to recent patent publication data.
Patents related to rare diseases and Covid-19 lead CSL’s portfolio
CSL has the highest number of patents in rare diseases followed by, Covid-19 and climate change. For rare diseases, nearly 43% of patents were filed and 83% of patents were granted in Q3 2023.
Hyperphosphatemia related patents lead CSL portfolio followed by renal insufficiency, and mobiles, hand-helds, pdas, smartphones
CSL has highest number of patents in hyperphosphatemia followed by renal insufficiency, mobiles, hand-helds, pdas, smartphones, caries and stroke. For hyperphosphatemia, nearly 0% of patents were filed and 12% of patents were granted in Q3 2023.
For comprehensive analysis of CSL‘s filings and grants, buy the databook here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Source link
#CSL #sees #highest #filings #grants #August